Clinical Trial Update: Efficacy and Safety of Escitalopram Doses up to 50mg in Treatment of MDD [Phase 4]

View source ↗

Summary

Phase 4 trial assessing the efficacy and safety of escitalopram at doses up to 50 mg for major depressive disorder. The study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Escitalopram (escitalopram)

Snippet

Sponsor: Community Pharmacology Services Ltd | Conditions: Major Depressive Disorder | Phase 4 | Status: COMPLETED